Short Interest in Pharming Group (NASDAQ:PHAR) Expands By 165.6%

Pharming Group (NASDAQ:PHAR - Get Free Report) was the recipient of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 25,500 shares, an increase of 165.6% from the October 31st total of 9,600 shares. Based on an average trading volume of 6,600 shares, the days-to-cover ratio is currently 3.9 days.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Oppenheimer cut their price target on Pharming Group from $31.00 to $30.00 and set an "outperform" rating on the stock in a research note on Monday, October 28th. HC Wainwright reissued a "buy" rating and issued a $37.00 target price on shares of Pharming Group in a research note on Thursday, October 24th.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its position in Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 41,110 shares of the company's stock after buying an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 as of its most recent filing with the SEC. 0.03% of the stock is owned by institutional investors and hedge funds.

Pharming Group Trading Up 1.7 %

NASDAQ:PHAR traded up $0.13 during trading hours on Thursday, hitting $7.58. The stock had a trading volume of 4,558 shares, compared to its average volume of 5,061. The business's 50 day moving average is $8.25 and its 200-day moving average is $8.24. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The company has a market cap of $513.81 million, a price-to-earnings ratio of -29.13 and a beta of 0.13. Pharming Group has a one year low of $6.65 and a one year high of $13.20.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.